BusinessDr. Joseph DeSanto and BioCorRx Recovery Program Participant Appear on the TV Show, The DoctorsBy Nasdaq OMXFeb 15, 2018, 1:01 PM UTC
BusinessBioCorRx Announces Results of Pre-IND meeting with FDA for Sustained Release Naltrexone Implant, BICX102By Nasdaq OMXFeb 12, 2018, 2:23 PM UTC
BusinessBioCorRx Extends Service Agreement with Dr. Balbir S. Brar as VP of Drug Development Following Pre-IND Meeting with the U.S. FDABy Nasdaq OMXFeb 8, 2018, 12:31 PM UTC
BusinessBioCorRx Completes Pre-IND Meeting with FDA; Reports Company to Move Forward with BICX102By Nasdaq OMXJan 26, 2018, 12:30 PM UTC
BusinessBioCorRx CEO, Brady Granier, Appears on Fox & Friends to Discuss the Opioid EpidemicBy Nasdaq OMXJan 2, 2018, 12:30 PM UTC
BusinessBioCorRx Submits Pre-IND Package to FDA for its Naltrexone Implant, BICX102By Nasdaq OMXDec 19, 2017, 12:30 PM UTC
